Official Warnings Concerning Diabetes and Blood Glucose Monitoring for Abilify (Aripiprazole)

Official Warnings Concerning Diabetes and Blood Glucose Monitoring for Abilify (Aripiprazole)

​The Summary of Product Characteristics (SmPC) for Abilify (aripiprazole), authorized by the European Medicines Agency (EMA), contains strict warnings regarding metabolic risks, diabetes, and hyperglycemia under Section 4.4: "Special warnings and precautions for use".

​Official Warnings Regarding Diabetes and Glycemia

  • ​Risk of Severe Hyperglycemia: Cases of hyperglycemia, sometimes extreme and associated with ketoacidosis or hyperosmolar coma (which can be fatal), have been reported in patients treated with atypical antipsychotics, including aripiprazole.
  • ​Clinical Symptoms Monitoring: The protocol mandates active monitoring for key clinical signs of hyperglycemia in all patients taking Abilify:
    • ​Polydipsia (excessive and persistent thirst)
    • ​Polyuria (increased frequency and volume of urination)
    • ​Polyphagia (excessive hunger)
    • ​Asthenia / Severe fatigue
  • ​Regular Biological Monitoring: Regular fasting blood glucose monitoring is recommended:
    • ​Mandatory in patients with pre-existing diabetes to detect any deterioration in glycemic control.
    • ​In patients presenting risk factors (family history of diabetes, obesity, weight gain during treatment).
  • ​Patient and Family Information: Prescribers are required to inform patients and their families so they can immediately identify these warning symptoms and perform blood glucose testing without delay.

​Official Reference Documents

  • ​European SmPC for Abilify (EMA): Available in the European Union Community Register database (ec.europa.eu/health/documents/community-register).
  • ​Public Information Leaflet (E-Compendium / FAMHP): Explicitly mentions, under precautions and severe side effects, the onset or worsening of diabetes requiring immediate medical consultation.

Comments

Post a Comment

Popular posts from this blog

Diabetic complications induced by Abilify (aripiprazole) - no glucose monitoring -

Image
IN MEMORIAM Anthony Santin y Ogueta  (25 juillet 1992 — 5 mai 2024) Death following diabetic complications induced by Abilify (aripiprazole) and no glucose monitoring during 9 years and, moreover, having been the subject of psychological abuse Here follows the sad story of my Son : COMPLAINT  TO THE NATIONAL MEDICAL BOARD Date By Registered Mail XXXXXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXXXXXX SUBJECT: Complaint against Psychiatrist XXXXXXXXXXX Dear Sir, I hereby file a complaint with the XXXXXXXXXX against psychiatrist XXXXXXXXXX for breach of duty of care, which resulted in the death of my son,  Anthony SANTIN Y OGUETA, 31 years old,  and also I file a complaint for psychological mistreatments (see at the end of this document). A- BACKGROUND: My son, at the age of 18, suffered a severe panic attack—this occurred during the period of the divorce of his parents. He was initially hospitalized in XXXXXX for four months to manage his anxiety. He was prescribed the medication H...
Read more

FR - SYNTHESE

Image
L’ordonnance du silence : Autopsie d’une faillite psychiatrique et humaine Anthony Santin y Ogueta,  l'histoire d'un jeune homme, prisonnier sans recours, du goulag psychiatrique jusqu'à sa mort prématurée. 1. Introduction : L'histoire d'une sentinelle oubliée Anthony avait 31 ans. Féru d’informatique et passionné par l'univers de  One Piece , il était un jeune homme bilingue dont la vie s'est brisée sur l'autel d'une médecine devenue aveugle. Son calvaire n'a pas commencé par une crise, mais par une incarcération : dès son entrée dans le système de soin, il fut jeté dans une cellule d'observation aux barreaux de fer, dans des conditions strictement carcérales. Ce traumatisme initial a scellé sa méfiance envers le corps médical, faisant de lui une sentinelle oubliée dans un système déshumanisé. Le paradoxe est insoutenable : le traitement censé le stabiliser, l’Abilify, est devenu l'instrument de sa fin. Faute de suivi, ce neuroleptique a...
Read more